<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Antibacterials: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i127.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i127.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i127.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i125.htm" title="Previous: Propafenone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1069.htm" title="Next: Tigecycline">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i127">Antibacterials</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Antibacterials</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i1058.htm" name="_1058">Typhoid Vaccine (oral)</a></td><td> antibacterials inactivate oral typhoid vaccine—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="6528.htm#_6528">section 14.4</a></td><td></td></tr></tbody></table><p><b>Tigecycline</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i220.htm">Coumarins</a></td><td> tigecycline possibly enhances anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr></tbody></table><p><b>Daptomycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of myopathy when  daptomycin given with ciclosporin (preferably avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i594.htm">Fibrates</a></td><td class="cBV"><b>increased risk of myopathy when  daptomycin given with fibrates (preferably avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i600.htm">Statins</a></td><td class="cBV"><b>increased risk of myopathy when  daptomycin given with statins (preferably avoid concomitant use)</b></td><td></td></tr></tbody></table><p><b>Co-trimoxazole</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><div>Co-trimoxazole interactions as for trimethoprim and sulfamethoxazole</div><p><b>Telithromycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










































<tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> telithromycin possibly increases plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with atazanavir in severe renal and hepatic impairment</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  telithromycin given with atorvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  telithromycin advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td class="cBV"><b> telithromycin possibly inhibits metabolism of calcium-channel blockers (increased risk of side-effects)</b></td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  telithromycin reduced by carbamazepine (avoid during and for 2 weeks after carbamazepine)</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> telithromycin possibly increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> telithromycin possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> telithromycin possibly increases plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  telithromycin advised by manufacturer of dronedarone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> telithromycin increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  telithromycin given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> telithromycin possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  telithromycin given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with fosamprenavir in severe renal and hepatic impairment</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with indinavir in severe renal and hepatic impairment</b></td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> telithromycin possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with ketoconazole in severe renal and hepatic impairment</b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  telithromycin advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with lopinavir in severe renal and hepatic impairment</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> telithromycin possibly increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> telithromycin inhibits metabolism of midazolam (increased plasma concentration  with increased sedation)</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with nelfinavir in severe renal and hepatic impairment</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>avoidance of  telithromycin advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i901.htm">Oxycodone</a></td><td> telithromycin inhibits the metabolism of oxycodone </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  telithromycin advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  telithromycin reduced by phenobarbital (avoid during and for 2 weeks after phenobarbital)</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  telithromycin reduced by phenytoin (avoid during and for 2 weeks after phenytoin)</b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  telithromycin given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i604.htm">Pravastatin</a></td><td>possible increased risk of myopathy when  telithromycin given with pravastatin </td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td> telithromycin possibly increases plasma concentration of quetiapine </td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> telithromycin possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  telithromycin reduced by rifampicin (avoid during and for 2 weeks after rifampicin)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with ritonavir in severe renal and hepatic impairment</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with saquinavir in severe renal and hepatic impairment</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> telithromycin possibly increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  telithromycin given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> telithromycin increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  telithromycin reduced by St John's wort (avoid during and for 2 weeks after St John's wort)</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> telithromycin possibly increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  telithromycin given with telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>manufacturer of  telithromycin advises avoid concomitant use with tipranavir in severe renal and hepatic impairment</b></td><td></td></tr></tbody></table><p><b>Aminoglycosides</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>















<tr><td><a href="41001i290.htm">Amphotericin</a></td><td>increased risk of nephrotoxicity when  aminoglycosides given with amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i458.htm">Bisphosphonates</a></td><td>increased risk of hypocalcaemia when  aminoglycosides given with bisphosphonates </td><td></td></tr><tr><td><a href="41001i137.htm">Capreomycin</a></td><td>increased risk of nephrotoxicity and ototoxicity when  aminoglycosides given with capreomycin </td><td></td></tr><tr><td><a href="41001i141.htm">Cephalosporins</a></td><td>possible increased risk of nephrotoxicity when  aminoglycosides given with cephalosporins </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  aminoglycosides given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i190.htm">Colistimethate Sodium</a></td><td>increased risk of nephrotoxicity when  aminoglycosides given with colistimethate sodium </td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td class="cBV"><b>increased risk of otoxicity when  aminoglycosides given with loop diuretics </b></td><td></td></tr><tr><td><a href="41001i620.htm">Muscle Relaxants, non-depolarising</a></td><td class="cBV"><b> aminoglycosides enhance effects of non-depolarising muscle relaxants </b></td><td></td></tr><tr><td><a href="41001i647.htm">Neostigmine</a></td><td class="cBV"><b> aminoglycosides antagonise effects of neostigmine </b></td><td></td></tr><tr><td><a href="41001i512.htm">Platinum Compounds</a></td><td class="cBV"><b>increased risk of nephrotoxicity and possibly of ototoxicity when  aminoglycosides given with platinum compounds </b></td><td></td></tr><tr><td><a href="41001i189.htm">Polymyxins</a></td><td>increased risk of nephrotoxicity when  aminoglycosides given with polymyxins </td><td></td></tr><tr><td><a href="41001i648.htm">Pyridostigmine</a></td><td class="cBV"><b> aminoglycosides antagonise effects of pyridostigmine </b></td><td></td></tr><tr><td><a href="41001i628.htm">Suxamethonium</a></td><td class="cBV"><b> aminoglycosides enhance effects of suxamethonium </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  aminoglycosides given with tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td class="cBV"><b>increased risk of nephrotoxicity and ototoxicity when  aminoglycosides given with vancomycin </b></td><td></td></tr></tbody></table><p><b>Amikacin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i70.htm">Indometacin</a></td><td>plasma concentration of  amikacin in neonates possibly increased by indometacin </td><td></td></tr></tbody></table><p><b>Framycetin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Gentamicin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i1012.htm">Agalsidase Alfa and Beta</a></td><td> gentamicin possibly inhibits effects of agalsidase alfa and beta (manufacturers of agalsidase alfa and beta advise avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> gentamicin possibly increases plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i70.htm">Indometacin</a></td><td>plasma concentration of  gentamicin in neonates possibly increased by indometacin </td><td></td></tr></tbody></table><p><b>Neomycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i1.htm">Acarbose</a></td><td> neomycin possibly enhances hypoglycaemic effect of acarbose , also severity of gastro-intestinal effects increased</td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b>experience in anticoagulant clinics suggests that INR possibly altered when  neomycin (given for local action on gut) is given with coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> neomycin reduces absorption of digoxin </td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td> neomycin possibly reduces absorption of methotrexate </td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b>experience in anticoagulant clinics suggests that INR possibly altered when  neomycin (given for local action on gut) is given with phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i176.htm">Phenoxymethylpenicillin</a></td><td> neomycin reduces absorption of phenoxymethylpenicillin </td><td></td></tr><tr><td><a href="41001i1074.htm">Sorafenib</a></td><td> neomycin reduces bioavailability of sorafenib </td><td></td></tr><tr><td><a href="41001i833.htm">Vitamin A</a></td><td> neomycin possibly reduces absorption of vitamin A </td><td></td></tr></tbody></table><p><b>Streptomycin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Tobramycin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Capreomycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td>increased risk of nephrotoxicity and ototoxicity when  capreomycin given with aminoglycosides </td><td></td></tr><tr><td><a href="41001i190.htm">Colistimethate Sodium</a></td><td>increased risk of nephrotoxicity when  capreomycin given with colistimethate sodium </td><td></td></tr><tr><td><a href="41001i512.htm">Platinum Compounds</a></td><td>increased risk of nephrotoxicity and ototoxicity when  capreomycin given with platinum compounds </td><td></td></tr><tr><td><a href="41001i189.htm">Polymyxins</a></td><td>increased risk of nephrotoxicity when  capreomycin given with polymyxins </td><td></td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td>increased risk of nephrotoxicity and ototoxicity when  capreomycin given with vancomycin </td><td></td></tr></tbody></table><p><b>Carbapenems</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i286.htm">Valproate</a></td><td class="cBV"><b> carbapenems reduce plasma concentration of valproate—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Doripenem</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  doripenem reduced by probenecid (manufacturers of doripenem advise avoid concomitant use)</td><td></td></tr></tbody></table><p><b>Ertapenem</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Imipenem with Cilastatin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i395.htm">Ganciclovir</a></td><td class="cBV"><b>increased risk of convulsions when  imipenem with cilastatin given with ganciclovir </b></td><td>Increased risk of myelosuppression with other myelosuppressive drugs—consult product literature</td></tr></tbody></table><p><b>Meropenem</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  meropenem reduced by probenecid </td><td></td></tr></tbody></table><p><b>Cephalosporins</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td>possible increased risk of nephrotoxicity when  cephalosporins given with aminoglycosides </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> cephalosporins possibly enhance anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  cephalosporins reduced by probenecid (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Cefaclor</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  cefaclor reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr></tbody></table><p><b>Cefadroxil</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Cefalexin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Cefixime</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Cefotaxime</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Cefpodoxime</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  cefpodoxime reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>absorption of  cefpodoxime reduced by histamine H<sub>2</sub>-antagonists </td><td></td></tr></tbody></table><p><b>Cefradine</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Ceftazidime</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Ceftriaxone</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Cefuroxime</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Chloramphenicol</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> chloramphenicol possibly increases plasma concentration of ciclosporin </b></td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> chloramphenicol possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of  chloramphenicol with clozapine (increased risk of agranulocytosis)</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> chloramphenicol enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1007.htm">Hydroxocobalamin</a></td><td> chloramphenicol reduces response to hydroxocobalamin </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>metabolism of  chloramphenicol possibly accelerated by phenobarbital (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> chloramphenicol increases plasma concentration of phenytoin (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  chloramphenicol accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td class="cBV"><b> chloramphenicol enhances effects of sulfonylureas </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> chloramphenicol possibly increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr></tbody></table><p><b>Clindamycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i620.htm">Muscle Relaxants, non-depolarising</a></td><td class="cBV"><b> clindamycin enhances effects of non-depolarising muscle relaxants </b></td><td></td></tr><tr><td><a href="41001i647.htm">Neostigmine</a></td><td> clindamycin antagonises effects of neostigmine </td><td></td></tr><tr><td><a href="41001i648.htm">Pyridostigmine</a></td><td> clindamycin antagonises effects of pyridostigmine </td><td></td></tr><tr><td><a href="41001i628.htm">Suxamethonium</a></td><td class="cBV"><b> clindamycin enhances effects of suxamethonium </b></td><td></td></tr></tbody></table><p><b>Cycloserine</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i20.htm">Alcohol</a></td><td class="cBV"><b>increased risk of convulsions when  cycloserine given with alcohol </b></td><td></td></tr><tr><td><a href="41001i165.htm">Isoniazid</a></td><td>increased risk of CNS toxicity when  cycloserine given with isoniazid </td><td></td></tr></tbody></table><p><b>Dapsone</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  dapsone reduced by probenecid (increased risk of side-effects)</td><td></td></tr><tr><td><a href="41001i199.htm">Rifamycins</a></td><td>plasma concentration of  dapsone reduced by rifamycins </td><td>Interactions do not apply to rifaximin</td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  dapsone given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td>plasma concentration of both drugs may increase when  dapsone given with trimethoprim </td><td></td></tr></tbody></table><p><b>Fusidic Acid</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  fusidic acid given with ritonavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i600.htm">Statins</a></td><td class="cBV"><b>risk of myopathy and rhabdomyolysis when  fusidic acid given with statins—avoid concomitant use and for 7 days after last fusidic acid dose</b></td><td></td></tr><tr><td><a href="41001i1127.htm">Sugammadex</a></td><td> fusidic acid possibly reduces response to sugammadex </td><td></td></tr></tbody></table><p><b>Isoniazid</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>











<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  isoniazid reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> isoniazid increases plasma concentration of carbamazepine (also possibly increased isoniazid hepatotoxicity)</b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td>plasma concentration of  isoniazid possibly reduced by corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i160.htm">Cycloserine</a></td><td>increased risk of CNS toxicity when  isoniazid given with cycloserine </td><td></td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td> isoniazid inhibits the metabolism of diazepam </td><td></td></tr><tr><td><a href="41001i523.htm">Disulfiram</a></td><td> isoniazid possibly increases CNS effects of disulfiram </td><td></td></tr><tr><td><a href="41001i281.htm">Ethosuximide</a></td><td class="cBV"><b> isoniazid inhibits metabolism of ethosuximide (increased plasma concentration and risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td> isoniazid possibly reduces plasma concentration of ketoconazole </td><td></td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td> isoniazid possibly reduces effects of levodopa </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> isoniazid possibly inhibits metabolism of phenytoin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> isoniazid possibly increases plasma concentration of theophylline </td><td></td></tr></tbody></table><p><b>Linezolid</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><div>Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  linezolid reduced by rifampicin (possible therapeutic failure of linezolid)</td><td></td></tr></tbody></table><p><b>Macrolides</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><div><i>See also</i> Telithromycin</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  macrolides advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i556.htm">Bromocriptine</a></td><td> macrolides possibly increase plasma concentration of bromocriptine (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i557.htm">Cabergoline</a></td><td> macrolides possibly increase plasma concentration of cabergoline (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> macrolides possibly inhibit metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> macrolides increase plasma concentration of digoxin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  macrolides advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  macrolides given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b> macrolides possibly inhibit metabolism of mizolastine (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i231.htm">Reboxetine</a></td><td class="cBV"><b>avoidance of  macrolides advised by manufacturer of reboxetine </b></td><td></td></tr></tbody></table><p><b>Azithromycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  azithromycin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> azithromycin possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> azithromycin possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> azithromycin possibly increases plasma concentration of disopyramide (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td>plasma concentration of  azithromycin increased by nelfinavir (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>increased risk of side-effects including neutropenia when  azithromycin given with rifabutin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  azithromycin possibly increased by ritonavir </td><td></td></tr></tbody></table><p><b>Clarithromycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

















































<tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> clarithromycin possibly increases plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td>plasma concentration of both drugs increased when  clarithromycin given with atazanavir </td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of atorvastatin </b></td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  clarithromycin advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td class="cBV"><b> clarithromycin possibly inhibits metabolism of calcium-channel blockers (increased risk of side-effects)</b></td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> clarithromycin inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> clarithromycin possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> clarithromycin enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of disopyramide (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  clarithromycin advised by manufacturer of dronedarone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>increased risk of rash when  clarithromycin given with efavirenz </td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of etravirine , also plasma concentration of clarithromycin reduced</b></td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  clarithromycin given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td> clarithromycin increases plasma concentration of itraconazole </td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td> clarithromycin possibly increases plasma concentration of methylprednisolone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> clarithromycin inhibits metabolism of midazolam (increased plasma concentration  with increased sedation)</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  clarithromycin reduced by nevirapine (but concentration of an active metabolite increased), also plasma concentration of nevirapine increased</td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b>avoidance of  clarithromycin advised by manufacturer of nilotinib </b></td><td></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>plasma concentration of both drugs increased when  clarithromycin given with omeprazole </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  clarithromycin advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> clarithromycin inhibits metabolism of phenytoin (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  clarithromycin given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i604.htm">Pravastatin</a></td><td> clarithromycin increases plasma concentration of pravastatin </td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td> clarithromycin enhances effects of repaglinide </td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of rifabutin (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i199.htm">Rifamycins</a></td><td>plasma concentration of  clarithromycin reduced by rifamycins </td><td>Interactions do not apply to rifaximin</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  clarithromycin increased by ritonavir (reduce dose of clarithromycin in renal impairment)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  clarithromycin given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> clarithromycin possibly increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  clarithromycin given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> clarithromycin increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td> clarithromycin possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  clarithromycin given with telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> clarithromycin possibly increases plasma concentration of theophylline </td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b> clarithromycin possibly increases plasma concentration of ticagrelor—manufacturer of ticagrelor advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  clarithromycin increased by tipranavir (reduce dose of clarithromycin in renal impairment), also clarithromycin increases plasma concentration of tipranavir</b></td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  clarithromycin advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i255.htm">Trazodone</a></td><td> clarithromycin possibly increases plasma concentration of trazodone </td><td></td></tr><tr><td><a href="41001i1085.htm">Vinorelbine</a></td><td class="cBV"><b>possible increased risk of neutropenia when  clarithromycin given with vinorelbine </b></td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td> clarithromycin tablets reduce absorption of zidovudine (give at least 2 hours apart)</td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr></tbody></table><p><b>Erythromycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><div>Interactions do not apply to small amounts of erythromycin used topically</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






























































<tr><td><a href="41001i86.htm">Alfentanil</a></td><td> erythromycin increases plasma concentration of alfentanil </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  erythromycin given with amisulpride—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  erythromycin given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>possible increased risk of myopathy when  erythromycin given with atorvastatin </td><td></td></tr><tr><td><a href="41001i556.htm">Bromocriptine</a></td><td> erythromycin increases plasma concentration of bromocriptine (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td> erythromycin increases plasma concentration of buspirone (reduce dose of buspirone)</td><td></td></tr><tr><td><a href="41001i557.htm">Cabergoline</a></td><td> erythromycin increases plasma concentration of cabergoline (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td class="cBV"><b> erythromycin possibly inhibits metabolism of calcium-channel blockers (increased risk of side-effects)</b></td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> erythromycin increases plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> erythromycin inhibits metabolism of ciclosporin (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i940.htm">Cilostazol</a></td><td> erythromycin increases plasma concentration of cilostazol (consider reducing dose of cilostazol)</td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  erythromycin increased by cimetidine (increased risk of toxicity, including deafness)</td><td></td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> erythromycin possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b> erythromycin possibly increases plasma concentration of clozapine (possible increased risk of convulsions)</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i483.htm">Colchicine</a></td><td class="cBV"><b> erythromycin possibly increases risk of colchicine toxicity—suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)</b></td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td> erythromycin possibly inhibits metabolism of corticosteroids </td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> erythromycin enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1076.htm">Darifenacin</a></td><td> erythromycin possibly increases plasma concentration of darifenacin </td><td></td></tr><tr><td><a href="41001i1172.htm">Dienogest</a></td><td> erythromycin increases plasma concentration of dienogest </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> erythromycin increases plasma concentration of disopyramide (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td><i>in vitro</i> studies suggest a possible interaction between  erythromycin and docetaxel (consult docetaxel product literature)</td><td></td></tr><tr><td><a href="41001i553.htm">Domperidone</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  erythromycin given with domperidone </b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b> erythromycin increases plasma concentration of dronedarone (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i963.htm">Eletriptan</a></td><td class="cBV"><b> erythromycin increases plasma concentration of eletriptan (risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td> erythromycin increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i640.htm">Estradiol</a></td><td> erythromycin increases plasma concentration of estradiol </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> erythromycin increases plasma concentration of everolimus </b></td><td></td></tr><tr><td><a href="41001i915.htm">Galantamine</a></td><td> erythromycin increases plasma concentration of galantamine </td><td></td></tr><tr><td><a href="41001i1050.htm">Ivabradine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  erythromycin given with ivabradine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i846.htm">Lercanidipine</a></td><td>avoidance of  erythromycin advised by manufacturer of lercanidipine </td><td></td></tr><tr><td><a href="41001i309.htm">Loratadine</a></td><td>manufacturer of loratadine advises  erythromycin possibly increases plasma concentration of loratadine </td><td></td></tr><tr><td><a href="41001i492.htm">Methylprednisolone</a></td><td> erythromycin inhibits the metabolism of methylprednisolone </td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> erythromycin inhibits metabolism of midazolam (increased plasma concentration  with increased sedation)</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b> erythromycin inhibits metabolism of mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with pentamidine isetionate </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>possible increased risk of ventricular arrhythmias when  erythromycin given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i604.htm">Pravastatin</a></td><td> erythromycin increases plasma concentration of pravastatin </td><td></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td class="cBV"><b> erythromycin increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b> erythromycin possibly increases plasma concentration of rifabutin (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  erythromycin possibly increased by ritonavir </td><td></td></tr><tr><td><a href="41001i974.htm">Rosuvastatin</a></td><td> erythromycin reduces plasma concentration of rosuvastatin </td><td></td></tr><tr><td><a href="41001i1155.htm">Rupatadine</a></td><td> erythromycin increases plasma concentration of rupatadine </td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  erythromycin given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td> erythromycin increases plasma concentration of sildenafil—reduce initial dose of sildenafil</td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  erythromycin given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  erythromycin given with sirolimus </b></td><td></td></tr><tr><td><a href="41001i371.htm">Sulpiride</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with sulpiride </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> erythromycin increases plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td> erythromycin possibly increases plasma concentration of tadalafil </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of both drugs possibly increased when  erythromycin given with telaprevir (increased risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> erythromycin increases plasma concentration of theophylline (also theophylline may reduce absorption of <i>oral</i> erythromycin)</b></td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td> erythromycin possibly increases plasma concentration of ticagrelor </td><td></td></tr><tr><td><a href="41001i850.htm">Tolterodine</a></td><td>avoidance of  erythromycin advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td> erythromycin possibly inhibits metabolism of valproate (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td> erythromycin increases plasma concentration of vardenafil (reduce dose of vardenafil)</td><td></td></tr><tr><td><a href="41001i1002.htm">Vinblastine</a></td><td class="cBV"><b> erythromycin increases toxicity of vinblastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i859.htm">Zafirlukast</a></td><td> erythromycin reduces plasma concentration of zafirlukast </td><td></td></tr><tr><td><a href="41001i426.htm">Zopiclone</a></td><td> erythromycin inhibits the metabolism of zopiclone </td><td></td></tr><tr><td><a href="41001i390.htm">Zuclopenthixol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when <i>parenteral</i>  erythromycin given with zuclopenthixol—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Methenamine</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>effects of  methenamine antagonised by acetazolamide </b></td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>avoid concomitant use of  methenamine with antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i800.htm">Potassium Citrate</a></td><td>avoid concomitant use of  methenamine with potassium citrate </td><td></td></tr><tr><td><a href="41001i1192.htm">Sodium Citrate</a></td><td>avoid concomitant use of  methenamine with sodium citrate </td><td></td></tr><tr><td><a href="41001i203.htm">Sulfonamides</a></td><td class="cBV"><b>increased risk of crystalluria when  methenamine given with sulfonamides </b></td><td></td></tr></tbody></table><p><b>Monobactams</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Aztreonam</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> aztreonam possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr></tbody></table><p><b>Nitrofurantoin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i113.htm">Magnesium Salts (oral)</a></td><td>absorption of  nitrofurantoin reduced by oral magnesium salts (as magnesium trisilicate)</td><td></td></tr><tr><td><a href="41001i196.htm">Nalidixic Acid</a></td><td> nitrofurantoin possibly antagonises effects of nalidixic acid </td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  nitrofurantoin reduced by probenecid (increased risk of side-effects)</td><td></td></tr><tr><td><a href="41001i689.htm">Sulfinpyrazone</a></td><td>excretion of  nitrofurantoin reduced by sulfinpyrazone (increased risk of toxicity)</td><td></td></tr></tbody></table><p><b>Nitroimidazoles</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Metronidazole</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><div>Interactions do not apply to topical metronidazole preparations </div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i20.htm">Alcohol</a></td><td>disulfiram-like reaction when  metronidazole given with alcohol </td><td></td></tr><tr><td><a href="41001i993.htm">Busulfan</a></td><td class="cBV"><b> metronidazole increases plasma concentration of busulfan (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  metronidazole inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> metronidazole enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i523.htm">Disulfiram</a></td><td>psychotic reaction reported when  metronidazole given with disulfiram </td><td></td></tr><tr><td><a href="41001i509.htm">Fluorouracil</a></td><td> metronidazole inhibits metabolism of fluorouracil (increased toxicity)</td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td> metronidazole increases risk of lithium toxicity</td><td></td></tr><tr><td><a href="41001i520.htm">Mycophenolate</a></td><td> metronidazole possibly reduces bioavailability of mycophenolate </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>metabolism of  metronidazole accelerated by phenobarbital (reduced effect)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> metronidazole possibly inhibits metabolism of phenytoin (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Tinidazole</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i20.htm">Alcohol</a></td><td>possibility of disulfiram-like reaction when  tinidazole given with alcohol </td><td></td></tr></tbody></table><p><b>Penicillins</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i220.htm">Coumarins</a></td><td>an interaction between broad-spectrum  penicillins and coumarins has not been demonstrated in studies, but common experience in anticoagulant clinics is that INR can be altered</td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td> penicillins reduce excretion of methotrexate (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td>an interaction between broad-spectrum  penicillins and phenindione has not been demonstrated in studies, but common experience in anticoagulant clinics is that INR can be altered</td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  penicillins reduced by probenecid (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i689.htm">Sulfinpyrazone</a></td><td>excretion of  penicillins reduced by sulfinpyrazone </td><td></td></tr><tr><td><a href="41001i209.htm">Tetracyclines</a></td><td>effects of  penicillins possibly antagonised by tetracyclines </td><td></td></tr></tbody></table><p><b>Temocillin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Amoxicillin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i22.htm">Allopurinol</a></td><td>increased risk of rash when  amoxicillin given with allopurinol </td><td></td></tr></tbody></table><p><b>Co-amoxiclav</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Ampicillin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i22.htm">Allopurinol</a></td><td>increased risk of rash when  ampicillin given with allopurinol </td><td></td></tr></tbody></table><p><b>Benzylpenicillin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Co-fluampicil</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><div>Co-fluampicil interactions as for ampicillin and flucloxacillin</div><p><b>Flucloxacillin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Phenoxymethylpenicillin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i133.htm">Neomycin</a></td><td>absorption of  phenoxymethylpenicillin reduced by neomycin </td><td></td></tr></tbody></table><p><b>Piperacillin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i620.htm">Muscle Relaxants, non-depolarising</a></td><td> piperacillin enhances effects of non-depolarising muscle relaxants </td><td></td></tr><tr><td><a href="41001i628.htm">Suxamethonium</a></td><td> piperacillin enhances effects of suxamethonium </td><td></td></tr></tbody></table><p><b>Pivmecillinam</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i286.htm">Valproate</a></td><td class="cBV"><b>manufacturer of  pivmecillinam advises avoid concomitant use with valproate </b></td><td></td></tr></tbody></table><p><b>Ticarcillin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Polymyxins</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>











<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td>increased risk of nephrotoxicity when  polymyxins given with aminoglycosides </td><td></td></tr><tr><td><a href="41001i290.htm">Amphotericin</a></td><td>increased risk of nephrotoxicity when  polymyxins given with amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i137.htm">Capreomycin</a></td><td>increased risk of nephrotoxicity when  polymyxins given with capreomycin </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  polymyxins given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td class="cBV"><b>increased risk of otoxicity when  polymyxins given with loop diuretics </b></td><td></td></tr><tr><td><a href="41001i620.htm">Muscle Relaxants, non-depolarising</a></td><td class="cBV"><b> polymyxins enhance effects of non-depolarising muscle relaxants </b></td><td></td></tr><tr><td><a href="41001i647.htm">Neostigmine</a></td><td class="cBV"><b> polymyxins antagonise effects of neostigmine </b></td><td></td></tr><tr><td><a href="41001i512.htm">Platinum Compounds</a></td><td class="cBV"><b>increased risk of nephrotoxicity and possibly of ototoxicity when  polymyxins given with platinum compounds </b></td><td></td></tr><tr><td><a href="41001i648.htm">Pyridostigmine</a></td><td class="cBV"><b> polymyxins antagonise effects of pyridostigmine </b></td><td></td></tr><tr><td><a href="41001i628.htm">Suxamethonium</a></td><td class="cBV"><b> polymyxins enhance effects of suxamethonium </b></td><td></td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td>increased risk of nephrotoxicity when  polymyxins given with vancomycin </td><td></td></tr></tbody></table><p><b>Colistimethate Sodium</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td>increased risk of nephrotoxicity when  colistimethate sodium given with aminoglycosides </td><td></td></tr><tr><td><a href="41001i137.htm">Capreomycin</a></td><td>increased risk of nephrotoxicity when  colistimethate sodium given with capreomycin </td><td></td></tr><tr><td><a href="41001i218.htm">Vancomycin</a></td><td>increased risk of nephrotoxicity and ototoxicity when  colistimethate sodium given with vancomycin </td><td></td></tr></tbody></table><p><b>Polymyxin B</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Pyrazinamide</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i663.htm">Probenecid</a></td><td> pyrazinamide antagonises effects of probenecid </td><td></td></tr><tr><td><a href="41001i689.htm">Sulfinpyrazone</a></td><td> pyrazinamide antagonises effects of sulfinpyrazone </td><td></td></tr></tbody></table><p><b>Quinolones</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  quinolones advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  quinolones given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i1092.htm">Lanthanum</a></td><td>absorption of  quinolones possibly reduced by lanthanum (give at least 2 hours before or 4 hours after lanthanum)</td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>possible increased risk of convulsions when  quinolones given with NSAIDs </b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i1026.htm">Strontium Ranelate</a></td><td>absorption of  quinolones reduced by strontium ranelate (manufacturer of strontium ranelate advises avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b>possible increased risk of convulsions when  quinolones given with theophylline </b></td><td></td></tr><tr><td><a href="41001i575.htm">Zolmitriptan</a></td><td> quinolones possibly inhibit metabolism of zolmitriptan (reduce dose of zolmitriptan)</td><td></td></tr></tbody></table><p><b>Moxifloxacin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






















<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  moxifloxacin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with tricyclics—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i385.htm">Benperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with benperidol—manufacturer of benperidol advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with chloroquine and hydroxychloroquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with droperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with <i>parenteral</i> erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i587.htm">Iron</a></td><td>absorption of  moxifloxacin reduced by <i>oral</i> iron </td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with mefloquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with pentamidine isetionate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with phenothiazines—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with quinine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  moxifloxacin reduced by sucralfate </td><td></td></tr><tr><td><a href="41001i803.htm">Zinc</a></td><td>absorption of  moxifloxacin reduced by zinc </td><td></td></tr><tr><td><a href="41001i390.htm">Zuclopenthixol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  moxifloxacin given with zuclopenthixol—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Ciprofloxacin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





















<tr><td><a href="41001i1145.htm">Agomelatine</a></td><td class="cBV"><b>avoidance of  ciprofloxacin advised by manufacturer of agomelatine </b></td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  ciprofloxacin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i465.htm">Calcium Salts</a></td><td>absorption of  ciprofloxacin reduced by calcium salts </td><td><i>see also</i> Antacids</td></tr><tr><td><a href="41001i865.htm">Clopidogrel</a></td><td class="cBV"><b> ciprofloxacin possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td> ciprofloxacin increases plasma concentration of clozapine </td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> ciprofloxacin enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i831.htm">Dairy Products</a></td><td>absorption of  ciprofloxacin reduced by dairy products </td><td></td></tr><tr><td><a href="41001i1024.htm">Duloxetine</a></td><td class="cBV"><b> ciprofloxacin inhibits metabolism of duloxetine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td> ciprofloxacin increases plasma concentration of erlotinib </td><td></td></tr><tr><td><a href="41001i587.htm">Iron</a></td><td>absorption of  ciprofloxacin reduced by <i>oral</i> iron </td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td> ciprofloxacin possibly reduces excretion of methotrexate (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i366.htm">Olanzapine</a></td><td> ciprofloxacin possibly increases plasma concentration of olanzapine </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> ciprofloxacin increases or decreases plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  ciprofloxacin reduced by probenecid (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td> ciprofloxacin increases plasma concentration of rasagiline </td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i686.htm">Ropinirole</a></td><td> ciprofloxacin inhibits metabolism of ropinirole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i1065.htm">Sevelamer</a></td><td>bioavailability of  ciprofloxacin reduced by sevelamer </td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  ciprofloxacin reduced by sucralfate </td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> ciprofloxacin increases plasma concentration of theophylline </b></td><td></td></tr><tr><td><a href="41001i805.htm">Tizanidine</a></td><td class="cBV"><b> ciprofloxacin increases plasma concentration of tizanidine (increased risk of toxicity)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i803.htm">Zinc</a></td><td>absorption of  ciprofloxacin reduced by zinc </td><td></td></tr></tbody></table><p><b>Levofloxacin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  levofloxacin given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  levofloxacin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1168.htm">Arsenic Trioxide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  levofloxacin given with arsenic trioxide </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td> levofloxacin possibly enhances anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i587.htm">Iron</a></td><td>absorption of  levofloxacin reduced by <i>oral</i> iron </td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td> levofloxacin possibly enhances anticoagulant effect of phenindione </td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  levofloxacin reduced by sucralfate </td><td></td></tr><tr><td><a href="41001i803.htm">Zinc</a></td><td>absorption of  levofloxacin reduced by zinc </td><td></td></tr></tbody></table><p><b>Nalidixic Acid</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> nalidixic acid enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i503.htm">Melphalan</a></td><td> nalidixic acid increases risk of melphalan toxicity</td><td></td></tr><tr><td><a href="41001i173.htm">Nitrofurantoin</a></td><td>effects of  nalidixic acid possibly antagonised by nitrofurantoin </td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  nalidixic acid reduced by probenecid (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Norfloxacin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>











<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  norfloxacin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> norfloxacin enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i831.htm">Dairy Products</a></td><td>absorption of  norfloxacin reduced by dairy products </td><td></td></tr><tr><td><a href="41001i270.htm">Glibenclamide</a></td><td> norfloxacin possibly enhances effects of glibenclamide </td><td></td></tr><tr><td><a href="41001i587.htm">Iron</a></td><td>absorption of  norfloxacin reduced by <i>oral</i> iron </td><td></td></tr><tr><td><a href="41001i520.htm">Mycophenolate</a></td><td> norfloxacin possibly reduces bioavailability of mycophenolate </td><td></td></tr><tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  norfloxacin reduced by probenecid (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  norfloxacin reduced by sucralfate </td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td class="cBV"><b> norfloxacin increases plasma concentration of theophylline </b></td><td></td></tr><tr><td><a href="41001i805.htm">Tizanidine</a></td><td> norfloxacin possibly increases plasma concentration of tizanidine (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i803.htm">Zinc</a></td><td>absorption of  norfloxacin reduced by zinc </td><td></td></tr></tbody></table><p><b>Ofloxacin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  ofloxacin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> ofloxacin enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i587.htm">Iron</a></td><td>absorption of  ofloxacin reduced by <i>oral</i> iron </td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  ofloxacin reduced by sucralfate </td><td></td></tr><tr><td><a href="41001i803.htm">Zinc</a></td><td>absorption of  ofloxacin reduced by zinc </td><td></td></tr></tbody></table><p><b>Rifamycins</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><div>Interactions do not apply to rifaximin</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i168.htm">Clarithromycin</a></td><td> rifamycins reduce plasma concentration of clarithromycin </td><td></td></tr><tr><td><a href="41001i484.htm">Corticosteroids</a></td><td class="cBV"><b> rifamycins accelerate metabolism of corticosteroids (reduced effect)</b></td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> rifamycins accelerate metabolism of coumarins (reduced anticoagulant effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i161.htm">Dapsone</a></td><td> rifamycins reduce plasma concentration of dapsone </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> rifamycins accelerate metabolism of disopyramide (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td class="cBV"><b> rifamycins accelerate metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> rifamycins accelerate metabolism of phenytoin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td class="cBV"><b> rifamycins accelerate metabolism of progestogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td class="cBV"><b> rifamycins possibly accelerate metabolism of sulfonylureas (reduced effect)</b></td><td></td></tr><tr><td><a href="41001i275.htm">Tolbutamide</a></td><td class="cBV"><b> rifamycins accelerate metabolism of tolbutamide (reduced effect)</b></td><td></td></tr></tbody></table><p><b>Rifabutin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



























<tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>plasma concentration of  rifabutin possibly increased by triazoles (increased risk of uveitis—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> rifabutin possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by atazanavir (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i431.htm">Atovaquone</a></td><td>avoidance of concomitant  rifabutin advised by manufacturer of atovaquone (plasma concentration of both drugs reduced)</td><td></td></tr><tr><td><a href="41001i167.htm">Azithromycin</a></td><td class="cBV"><b>increased risk of side-effects including neutropenia when  rifabutin given with azithromycin </b></td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  rifabutin advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> rifabutin reduces plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of   rifabutin increased by clarithromycin (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by darunavir (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  rifabutin reduced by efavirenz—increase dose of rifabutin</td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  rifabutin possibly increased by erythromycin (increased risk of toxicity—reduce rifabutin dose)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b>plasma concentration of both drugs reduced when  rifabutin given with etravirine </b></td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by fluconazole (increased risk of uveitis—reduce rifabutin dose)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by fosamprenavir (reduce dose of rifabutin)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by indinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b> rifabutin reduces plasma concentration of itraconazole—manufacturer of itraconazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  rifabutin advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by nelfinavir (halve dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  rifabutin possibly increased by nevirapine </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by posaconazole (also plasma concentration of posaconazole reduced)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of   rifabutin increased by ritonavir (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by saquinavir (also plasma concentration of saquinavir reduced)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> rifabutin reduces plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td> rifabutin possibly reduces plasma concentration of tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  rifabutin advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by tipranavir (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by voriconazole , also rifabutin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for rifabutin toxicity)</b></td><td></td></tr></tbody></table><p><b>Rifampicin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






















































































































<tr><td><a href="41001i907.htm">Abacavir</a></td><td> rifampicin possibly reduces plasma concentration of abacavir </td><td></td></tr><tr><td><a href="41001i86.htm">Alfentanil</a></td><td> rifampicin accelerates metabolism of alfentanil (reduced effect)</td><td></td></tr><tr><td><a href="41001i1099.htm">Aliskiren</a></td><td> rifampicin reduces plasma concentration of aliskiren </td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  rifampicin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td> rifampicin reduces plasma concentration of apixaban </td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> rifampicin reduces plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> rifampicin possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of atazanavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td> rifampicin possibly reduces plasma concentration of atorvastatin </td><td></td></tr><tr><td><a href="41001i431.htm">Atovaquone</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of atovaquone (and concentration of rifampicin increased)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td> rifampicin possibly accelerates metabolism of benzodiazepines (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i443.htm">Bisoprolol</a></td><td> rifampicin accelerates metabolism of bisoprolol (plasma concentration  significantly reduced)</td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of boceprevir (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of bosentan—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td> rifampicin possibly accelerates metabolism of buspirone </td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i445.htm">Carvedilol</a></td><td> rifampicin reduces plasma concentration of carvedilol </td><td></td></tr><tr><td><a href="41001i947.htm">Caspofungin</a></td><td> rifampicin initially increases and then reduces plasma concentration of caspofungin (consider increasing dose of caspofungin)</td><td></td></tr><tr><td><a href="41001i898.htm">Celecoxib</a></td><td> rifampicin reduces plasma concentration of celecoxib </td><td></td></tr><tr><td><a href="41001i446.htm">Celiprolol</a></td><td> rifampicin reduces plasma concentration of celiprolol </td><td></td></tr><tr><td><a href="41001i158.htm">Chloramphenicol</a></td><td> rifampicin accelerates metabolism of chloramphenicol (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> rifampicin accelerates metabolism of ciclosporin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td> rifampicin accelerates metabolism of cimetidine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td> rifampicin possibly reduces plasma concentration of clozapine </td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i88.htm">Codeine</a></td><td> rifampicin accelerates metabolism of codeine (reduced effect)</td><td></td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b> rifampicin significantly reduces plasma concentration of darunavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1077.htm">Dasatinib</a></td><td class="cBV"><b> rifampicin accelerates metabolism of dasatinib (reduced plasma  concentration—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1072.htm">Deferasirox</a></td><td> rifampicin reduces plasma concentration of deferasirox </td><td></td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td> rifampicin accelerates metabolism of diazepam (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i64.htm">Diclofenac</a></td><td> rifampicin reduces plasma concentration of diclofenac </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> rifampicin possibly reduces plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b> rifampicin accelerates metabolism of diltiazem (plasma concentration  significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i212.htm">Doxycycline</a></td><td> rifampicin reduces plasma concentration of doxycycline—consider increasing dose of doxycycline</td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td> rifampicin reduces plasma concentration of efavirenz—increase dose of efavirenz</td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1205.htm">Eribulin</a></td><td> rifampicin possibly reduces plasma concentration of eribulin </td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td> rifampicin accelerates metabolism of erlotinib (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i960.htm">Etoricoxib</a></td><td> rifampicin reduces plasma concentration of etoricoxib </td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td>avoidance of  rifampicin advised by manufacturer of etravirine </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of everolimus </b></td><td></td></tr><tr><td><a href="41001i1047.htm">Exemestane</a></td><td> rifampicin possibly reduces plasma concentration of exemestane </td><td></td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td> rifampicin accelerates metabolism of fentanyl (reduced effect)</td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td> rifampicin reduces plasma concentration of active metabolite of fesoterodine </td><td></td></tr><tr><td><a href="41001i308.htm">Fexofenadine</a></td><td> rifampicin possibly reduces effects of fexofenadine </td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b> rifampicin accelerates metabolism of fluconazole (reduced plasma concentration)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i603.htm">Fluvastatin</a></td><td> rifampicin accelerates metabolism of fluvastatin (reduced effect)</td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b> rifampicin significantly reduces plasma concentration of fosamprenavir—avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i1170.htm">Gefitinib</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of gefitinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b> rifampicin accelerates metabolism of haloperidol (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of imatinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i870.htm">Imidapril</a></td><td> rifampicin reduces plasma concentration of active metabolite of imidapril (reduced antihypertensive effect)</td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> rifampicin accelerates metabolism of indinavir (reduced plasma  concentration—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i472.htm">Isradipine</a></td><td class="cBV"><b> rifampicin possibly accelerates metabolism of isradipine (possible significantly reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of itraconazole—manufacturer of itraconazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b> rifampicin accelerates metabolism of ketoconazole (reduced plasma concentration), also plasma concentration of rifampicin may be reduced by ketoconazole</b></td><td></td></tr><tr><td><a href="41001i283.htm">Lamotrigine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of lamotrigine </b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i891.htm">Leflunomide</a></td><td> rifampicin possibly increases plasma concentration of active metabolite of leflunomide </td><td>Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</td></tr><tr><td><a href="41001i738.htm">Levothyroxine</a></td><td> rifampicin accelerates metabolism of levothyroxine (may increase requirements for levothyroxine in hypothyroidism)</td><td></td></tr><tr><td><a href="41001i1210.htm">Linagliptin</a></td><td> rifampicin possibly reduces effects of linagliptin </td><td></td></tr><tr><td><a href="41001i917.htm">Linezolid</a></td><td> rifampicin reduces plasma concentration of linezolid (possible therapeutic failure of linezolid)</td><td>Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of lopinavir—avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i108.htm">Losartan</a></td><td> rifampicin reduces plasma concentration of losartan and its active metabolite</td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of maraviroc—consider increasing dose of maraviroc</b></td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of mefloquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> rifampicin accelerates metabolism of methadone (reduced effect)</td><td></td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> rifampicin reduces plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i98.htm">Morphine</a></td><td> rifampicin accelerates metabolism of morphine (reduced effect)</td><td></td></tr><tr><td><a href="41001i520.htm">Mycophenolate</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of active metabolite of mycophenolate </b></td><td></td></tr><tr><td><a href="41001i920.htm">Nateglinide</a></td><td> rifampicin reduces plasma concentration of nateglinide </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b> rifampicin significantly reduces plasma concentration of nelfinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of nevirapine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i474.htm">Nicardipine</a></td><td class="cBV"><b> rifampicin possibly accelerates metabolism of nicardipine (possible significantly reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td class="cBV"><b> rifampicin accelerates metabolism of nifedipine (plasma concentration  significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of nilotinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i476.htm">Nimodipine</a></td><td class="cBV"><b> rifampicin accelerates metabolism of nimodipine (plasma concentration  significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i1045.htm">Ondansetron</a></td><td> rifampicin accelerates metabolism of ondansetron (reduced effect)</td><td></td></tr><tr><td><a href="41001i901.htm">Oxycodone</a></td><td> rifampicin possibly accelerates metabolism of oxycodone </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  rifampicin possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of posaconazole </b></td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b> rifampicin accelerates metabolism of propafenone (reduced effect)</b></td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td> rifampicin accelerates metabolism of propranolol (plasma concentration  significantly reduced)</td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of quinine </b></td><td></td></tr><tr><td><a href="41001i1111.htm">Raltegravir</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of raltegravir—consider increasing dose of raltegravir</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td> rifampicin possibly antagonises hypoglycaemic effect of repaglinide </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td> rifampicin possibly reduces plasma concentration of ritonavir </td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td> rifampicin reduces plasma concentration of rivaroxaban </td><td></td></tr><tr><td><a href="41001i1190.htm">Roflumilast</a></td><td> rifampicin reduces plasma concentration of roflumilast—consider increasing dose of roflumilast</td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> rifampicin significantly reduces plasma concentration of saquinavir , also risk of hepatotoxicity—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> rifampicin possibly reduces plasma concentration of simvastatin </td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1074.htm">Sorafenib</a></td><td> rifampicin reduces plasma concentration of sorafenib </td><td></td></tr><tr><td><a href="41001i1075.htm">Sunitinib</a></td><td> rifampicin accelerates metabolism of sunitinib (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i581.htm">Tamoxifen</a></td><td> rifampicin accelerates metabolism of tamoxifen (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  rifampicin significantly reduced by telaprevir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of telithromycin (avoid during and for 2 weeks after rifampicin)</b></td><td></td></tr><tr><td><a href="41001i1137.htm">Temsirolimus</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of active metabolite of temsirolimus—avoid concomitant use</b></td><td>The main active metabolite of temsirolimus is sirolimus—<i>see also</i> interactions of sirolimus and consult product literature</td></tr><tr><td><a href="41001i292.htm">Terbinafine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of terbinafine </b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> rifampicin accelerates metabolism of theophylline (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i737.htm">Tibolone</a></td><td> rifampicin accelerates metabolism of tibolone (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of ticagrelor </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b> rifampicin possibly reduces plasma concentration of tipranavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1158.htm">Tolvaptan</a></td><td> rifampicin reduces plasma concentration of tolvaptan </td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td> rifampicin possibly reduces plasma concentration of trimethoprim </td><td></td></tr><tr><td><a href="41001i1163.htm">Ulipristal</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b> rifampicin accelerates metabolism of verapamil (plasma concentration  significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i1181.htm">Vinflunine</a></td><td class="cBV"><b> rifampicin possibly reduces plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of voriconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i904.htm">Zaleplon</a></td><td> rifampicin accelerates metabolism of zaleplon (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td>avoidance of  rifampicin advised by manufacturer of zidovudine </td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr><tr><td><a href="41001i425.htm">Zolpidem</a></td><td> rifampicin accelerates metabolism of zolpidem (reduced plasma concentration and reduced effect)</td><td></td></tr><tr><td><a href="41001i426.htm">Zopiclone</a></td><td> rifampicin significantly reduces plasma concentration of zopiclone </td><td></td></tr></tbody></table><p><b>Sulfonamides</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>












<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  sulfonamides given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of  sulfonamides with clozapine (increased risk of agranulocytosis)</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> sulfonamides enhance anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i164.htm">Methenamine</a></td><td class="cBV"><b>increased risk of crystalluria when  sulfonamides given with methenamine </b></td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td> sulfonamides increase risk of methotrexate toxicity</td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td> sulfonamides possibly inhibit metabolism of phenindione </td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> sulfonamides possibly increase plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i661.htm">Potassium Aminobenzoate</a></td><td>effects of  sulfonamides inhibited by potassium aminobenzoate </td><td></td></tr><tr><td><a href="41001i873.htm">Prilocaine</a></td><td>increased risk of methaemoglobinaemia when  sulfonamides given with prilocaine </td><td></td></tr><tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td class="cBV"><b>increased antifolate effect when  sulfonamides given with pyrimethamine </b></td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> sulfonamides rarely enhance the effects of sulfonylureas </td><td></td></tr><tr><td><a href="41001i42.htm">Thiopental</a></td><td> sulfonamides enhance effects of thiopental </td><td></td></tr></tbody></table><p><b>Sulfadiazine</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> sulfadiazine possibly reduces plasma concentration of ciclosporin </b></td><td></td></tr></tbody></table><p><b>Sulfadoxine</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Sulfamethoxazole</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i118.htm">Amiodarone</a></td><td>possible increased risk of ventricular arrhythmias when  sulfamethoxazole (as co-trimoxazole) given with amiodarone—manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole</td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i519.htm">Azathioprine</a></td><td class="cBV"><b>increased risk of haematological toxicity when  sulfamethoxazole (as co-trimoxazole) given with azathioprine </b></td><td></td></tr><tr><td><a href="41001i510.htm">Mercaptopurine</a></td><td class="cBV"><b>increased risk of haematological toxicity when  sulfamethoxazole (as co-trimoxazole) given with mercaptopurine </b></td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b>increased risk of haematological toxicity when  sulfamethoxazole (as co-trimoxazole) given with methotrexate </b></td><td></td></tr></tbody></table><p><b>Tetracyclines</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>















<tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  tetracyclines reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> tetracyclines possibly enhance anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i831.htm">Dairy Products</a></td><td>absorption of  tetracyclines (except doxycycline and minocycline) reduced by dairy products </td><td></td></tr><tr><td><a href="41001i563.htm">Ergotamine and Methysergide</a></td><td>increased risk of ergotism when  tetracyclines given with ergotamine and methysergide </td><td></td></tr><tr><td><a href="41001i587.htm">Iron</a></td><td>absorption of  tetracyclines reduced by <i>oral</i> iron , also absorption of <i>oral</i> iron reduced by tetracyclines</td><td></td></tr><tr><td><a href="41001i14.htm">Kaolin</a></td><td>absorption of  tetracyclines possibly reduced by kaolin </td><td></td></tr><tr><td><a href="41001i174.htm">Penicillins</a></td><td> tetracyclines possibly antagonise effects of penicillins </td><td></td></tr><tr><td><a href="41001i223.htm">Phenindione</a></td><td class="cBV"><b> tetracyclines possibly enhance anticoagulant effect of phenindione </b></td><td>Change in patient’s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  </td></tr><tr><td><a href="41001i10.htm">Quinapril</a></td><td>absorption of  tetracyclines reduced by quinapril tablets (quinapril tablets contain magnesium carbonate)</td><td></td></tr><tr><td><a href="41001i682.htm">Retinoids</a></td><td class="cBV"><b>possible increased risk of benign intracranial hypertension when  tetracyclines given with retinoids (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1026.htm">Strontium Ranelate</a></td><td>absorption of  tetracyclines reduced by strontium ranelate (manufacturer of strontium ranelate advises avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i755.htm">Sucralfate</a></td><td>absorption of  tetracyclines reduced by sucralfate </td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> tetracyclines possibly enhance hypoglycaemic effect of sulfonylureas </td><td></td></tr><tr><td><a href="41001i756.htm">Tripotassium Dicitratobismuthate</a></td><td>absorption of  tetracyclines reduced by tripotassium dicitratobismuthate </td><td></td></tr><tr><td><a href="41001i803.htm">Zinc</a></td><td>absorption of  tetracyclines reduced by zinc , also absorption of zinc reduced by tetracyclines</td><td></td></tr></tbody></table><p><b>Demeclocycline</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Doxycycline</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>metabolism of  doxycycline accelerated by carbamazepine (reduced effect)</td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td> doxycycline increases risk of methotrexate toxicity</td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>metabolism of  doxycycline accelerated by phenobarbital (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>metabolism of  doxycycline accelerated by phenytoin (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  doxycycline reduced by rifampicin—consider increasing dose of doxycycline</td><td></td></tr></tbody></table><p><b>Lymecycline</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i524.htm">Diuretics</a></td><td>manufacturer of  lymecycline advises avoid concomitant use with diuretics </td><td></td></tr></tbody></table><p><b>Minocycline</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Oxytetracycline</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Tetracycline</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i431.htm">Atovaquone</a></td><td> tetracycline reduces plasma concentration of atovaquone </td><td></td></tr><tr><td><a href="41001i465.htm">Calcium Salts</a></td><td>absorption of  tetracycline reduced by calcium salts </td><td><i>see also</i> Antacids</td></tr><tr><td><a href="41001i593.htm">Colestipol</a></td><td>absorption of  tetracycline possibly reduced by colestipol </td><td>Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption </td></tr><tr><td><a href="41001i592.htm">Colestyramine</a></td><td>absorption of  tetracycline possibly reduced by colestyramine </td><td>Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td> tetracycline increases risk of methotrexate toxicity</td><td></td></tr></tbody></table><p><b>Teicoplanin</b> belongs to
      <b>Antibacterials</b>
          but has no specific interaction information.
        </p><p><b>Trimethoprim</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


















<tr><td><a href="41001i2.htm">ACE Inhibitors</a></td><td>possible increased risk of hyperkalaemia when  trimethoprim given with ACE inhibitors </td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td>possible increased risk of ventricular arrhythmias when  trimethoprim (as co-trimoxazole) given with amiodarone—manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole</td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i107.htm">Angiotensin-II Receptor Antagonists</a></td><td>possible increased risk of hyperkalaemia when  trimethoprim given with angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i519.htm">Azathioprine</a></td><td class="cBV"><b>increased risk of haematological toxicity when  trimethoprim (also with co-trimoxazole) given with azathioprine </b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  trimethoprim given with ciclosporin , also plasma concentration of ciclosporin reduced by <i>intravenous</i> trimethoprim</b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td> trimethoprim possibly enhances anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i161.htm">Dapsone</a></td><td>plasma concentration of both drugs may increase when  trimethoprim given with dapsone </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> trimethoprim possibly increases plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td>increased risk of hyperkalaemia when  trimethoprim given with eplerenone </td><td></td></tr><tr><td><a href="41001i399.htm">Lamivudine</a></td><td> trimethoprim (as co-trimoxazole) increases plasma concentration of lamivudine—avoid concomitant use of high-dose co-trimoxazole</td><td></td></tr><tr><td><a href="41001i510.htm">Mercaptopurine</a></td><td class="cBV"><b>increased risk of haematological toxicity when  trimethoprim (also with co-trimoxazole) given with mercaptopurine </b></td><td></td></tr><tr><td><a href="41001i511.htm">Methotrexate</a></td><td class="cBV"><b>increased risk of haematological toxicity when  trimethoprim (also with co-trimoxazole) given with methotrexate </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> trimethoprim increases plasma concentration of phenytoin (also increased antifolate effect)</b></td><td></td></tr><tr><td><a href="41001i340.htm">Pyrimethamine</a></td><td class="cBV"><b>increased antifolate effect when  trimethoprim given with pyrimethamine </b></td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td> trimethoprim possibly enhances hypoglycaemic effect of repaglinide—manufacturer advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  trimethoprim possibly reduced by rifampicin </td><td></td></tr><tr><td><a href="41001i549.htm">Spironolactone</a></td><td>possible increased risk of hyperkalaemia when  trimethoprim given with spironolactone </td><td></td></tr><tr><td><a href="41001i268.htm">Sulfonylureas</a></td><td> trimethoprim rarely enhances the effects of sulfonylureas </td><td></td></tr></tbody></table><p><b>Vancomycin</b> belongs to
      <b>Antibacterials</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>












<tr><td><a href="41001i128.htm">Aminoglycosides</a></td><td class="cBV"><b>increased risk of nephrotoxicity and ototoxicity when  vancomycin given with aminoglycosides </b></td><td></td></tr><tr><td><a href="41001i290.htm">Amphotericin</a></td><td>possible increased risk of nephrotoxicity when  vancomycin given with amphotericin </td><td>Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</td></tr><tr><td><a href="41001i39.htm">Anaesthetics, General</a></td><td>hypersensitivity-like reactions can occur when <i>intravenous</i>  vancomycin given with general anaesthetics </td><td><i>See also</i> Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="6559.htm#_6559.1">section 15.1</a>



</td></tr><tr><td><a href="41001i137.htm">Capreomycin</a></td><td>increased risk of nephrotoxicity and ototoxicity when  vancomycin given with capreomycin </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>increased risk of nephrotoxicity when  vancomycin given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i877.htm">Cisplatin</a></td><td>increased risk of nephrotoxicity and possibly of ototoxicity when  vancomycin given with cisplatin </td><td></td></tr><tr><td><a href="41001i592.htm">Colestyramine</a></td><td>effects of <i>oral</i>  vancomycin antagonised by colestyramine </td><td>Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption</td></tr><tr><td><a href="41001i190.htm">Colistimethate Sodium</a></td><td>increased risk of nephrotoxicity and ototoxicity when  vancomycin given with colistimethate sodium </td><td></td></tr><tr><td><a href="41001i539.htm">Diuretics, Loop</a></td><td class="cBV"><b>increased risk of otoxicity when  vancomycin given with loop diuretics </b></td><td></td></tr><tr><td><a href="41001i189.htm">Polymyxins</a></td><td>increased risk of nephrotoxicity when  vancomycin given with polymyxins </td><td></td></tr><tr><td><a href="41001i628.htm">Suxamethonium</a></td><td class="cBV"><b> vancomycin enhances effects of suxamethonium </b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td>possible increased risk of nephrotoxicity when  vancomycin given with tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1069.htm" title="Tigecycline">Tigecycline</a></li><li><a href="41001i1061.htm" title="Daptomycin">Daptomycin</a></li><li><a href="41001i938.htm" title="Co-trimoxazole">Co-trimoxazole</a></li><li><a href="41001i946.htm" title="Telithromycin">Telithromycin</a></li><li id="_41001i128"><a href="41001i128.htm" title="Aminoglycosides">Aminoglycosides</a></li><li><a href="41001i137.htm" title="Capreomycin">Capreomycin</a></li><li id="_41001i138"><a href="41001i138.htm" title="Carbapenems">Carbapenems</a></li><li id="_41001i141"><a href="41001i141.htm" title="Cephalosporins">Cephalosporins</a></li><li><a href="41001i158.htm" title="Chloramphenicol">Chloramphenicol</a></li><li><a href="41001i159.htm" title="Clindamycin">Clindamycin</a></li><li><a href="41001i160.htm" title="Cycloserine">Cycloserine</a></li><li><a href="41001i161.htm" title="Dapsone">Dapsone</a></li><li><a href="41001i163.htm" title="Fusidic Acid">Fusidic Acid</a></li><li><a href="41001i165.htm" title="Isoniazid">Isoniazid</a></li><li><a href="41001i917.htm" title="Linezolid">Linezolid</a></li><li id="_41001i166"><a href="41001i166.htm" title="Macrolides">Macrolides</a></li><li><a href="41001i164.htm" title="Methenamine">Methenamine</a></li><li id="_41001i171"><a href="41001i171.htm" title="Monobactams">Monobactams</a></li><li><a href="41001i173.htm" title="Nitrofurantoin">Nitrofurantoin</a></li><li id="_41001i785"><a href="41001i785.htm" title="Nitroimidazoles">Nitroimidazoles</a></li><li id="_41001i174"><a href="41001i174.htm" title="Penicillins">Penicillins</a></li><li id="_41001i189"><a href="41001i189.htm" title="Polymyxins">Polymyxins</a></li><li><a href="41001i192.htm" title="Pyrazinamide">Pyrazinamide</a></li><li id="_41001i193"><a href="41001i193.htm" title="Quinolones">Quinolones</a></li><li id="_41001i199"><a href="41001i199.htm" title="Rifamycins">Rifamycins</a></li><li id="_41001i203"><a href="41001i203.htm" title="Sulfonamides">Sulfonamides</a></li><li id="_41001i209"><a href="41001i209.htm" title="Tetracyclines">Tetracyclines</a></li><li><a href="41001i852.htm" title="Teicoplanin">Teicoplanin</a></li><li><a href="41001i217.htm" title="Trimethoprim">Trimethoprim</a></li><li><a href="41001i218.htm" title="Vancomycin">Vancomycin</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i125.htm">Previous: Propafenone</a> | <a class="top" href="41001i127.htm#">Top</a> | <a accesskey="]" href="41001i1069.htm">Next: Tigecycline</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>